TORRENT PHARMACEUTICALS LTD.

Torrent Pharmaceuticals Ltd. has enhanced its investment in Torrent Urja 27 Private Limited, a special purpose vehicle for a captive hybrid power project. The investment has increased from ₹7.92 Cr to ₹11.88 Cr, corresponding to an increase in project capacity. This move aims to boost the share of renewable power sources in the company's operations and comply with regulatory requirements for captive users. Torrent Urja is an associate company and a step-down subsidiary of Torrent Pharma's holding company, and the transaction is conducted on an arm's length basis. The acquisition of a 26% stake in Torrent Urja is expected to be completed within 18 to 21 months.

Torrent Pharmaceuticals Ltd has announced the closure of its trading window for designated persons. This closure is in accordance with the company's Code of Conduct and SEBI regulations. The window will remain shut from October 1st, 2026, until 48 hours after the submission of the financial results for the quarter ended September 30th, 2026, to the stock exchanges. This measure is standard practice to prevent insider trading ahead of financial disclosures.

Torrent Pharmaceuticals Ltd has been assigned an Environmental, Social, and Governance (ESG) Rating of 70 by NSE Sustainability Ratings and Analytics Limited, a SEBI-registered ESG Rating Provider. This rating reflects an independent assessment of the company's performance across environmental, social, and governance factors. The company has notified this development as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Ltd announced the approval of its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, following a Board Meeting held on July 30, 2026. The company will publish extracts of these results and make them available on its website. Additionally, Ameera Shah will complete her term as an Independent Director on August 1, 2026. The financial results were reviewed by B S R & Co. LLP.

Torrent Pharmaceuticals Ltd has announced a change in its Senior Management Personnel (SMP). Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni will cease to be part of the senior management team effective July 30, 2026. This change is attributed to a revised reporting structure within the company. The company has provided details as per SEBI regulations, confirming that these individuals are no longer designated as SMPs from the specified date.

Torrent Pharmaceuticals Ltd. announced that its Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company will publish an extract of the consolidated financial results as per listing regulations and will make both standalone and consolidated results available on its website. A press release detailing the financial results has also been issued. Additionally, the company noted that Ameera Shah will complete her term as an Independent Director on August 1, 2026. The Board meeting commenced at 2:00 PM and concluded at 4:40 PM.

Torrent Pharmaceuticals Ltd. has announced the appointment of Shanti Ekambaram as an Additional Independent Director to its Board of Directors. This appointment, effective from July 30, 2026, is for a term of three consecutive years, subject to shareholder approval. Ms. Ekambaram brings extensive experience, with 39 years in financial services, including a significant 35-year tenure at Kotak Mahindra Bank, where she held the position of Deputy Managing Director and Whole-time Director. Her expertise spans banking, capital markets, and governance. She is not related to any existing directors and is not debarred from holding a directorship.

Torrent Pharmaceuticals Limited has received final listing and trading approval from NSE and BSE for 4,19,22,416 fully paid-up equity shares. These shares were issued and allotted pursuant to the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The shares were previously allotted to eligible shareholders of J. B. Chemicals on July 20, 2026, based on the record date of July 17, 2026. The shares will be listed and admitted to dealings on both exchanges effective July 28, 2026.

Torrent Pharmaceuticals Ltd. has announced the allotment of 4,19,22,416 fully paid-up equity shares to the eligible shareholders of J. B. Chemicals & Pharmaceuticals Ltd. This allotment is a consequence of the Scheme of Amalgamation between the two companies, sanctioned by the National Company Law Tribunal (NCLT). The record date for this allotment was July 17, 2026. The share exchange ratio was 51 Torrent Pharma shares for every 100 J. B. Chemicals shares. This corporate action will increase Torrent Pharma's issued and paid-up equity share capital from ₹1,69,22,27,200 to ₹1,90,18,39,280. The newly allotted shares will rank pari passu with existing shares.

Torrent Pharmaceuticals Ltd. has announced the voluntary dissolution of its wholly-owned subsidiary, Curatio Inc., domiciled in the Philippines. The dissolution was effective from July 10, 2026, with the company receiving official communication on July 17, 2026. The subsidiary contributed nil to the company's turnover for FY 2025-26 and had a net worth of ₹1.3 Crores, representing 0.02% of the parent company's net worth. The dissolution was achieved by shortening the term of existence via an amendment in the Articles of Incorporation, and therefore, sale-related disclosures like consideration or buyer details are not applicable.